文献速递心脑血管急症

曼彻斯特急性冠脉综合征决策规则在急性冠脉综合征中的诊断性能:系统评价与荟萃分析

Performance of Manchester Acute Coronary Syndromes decision rules in acute coronary syndrome: a systematic review and meta-analysis.
PubMed 文献 · Eur J Emerg Med · 2024-06-11
一句话结论T-MACS对急性心肌梗死和30天主要不良心脏事件的诊断性能良好(灵敏度98%/96%,特异度35%/36%),是三种MACS模型中综合准确率最高者。

该系统评价与荟萃分析检索Medline、Embase、Scopus和Web of Science至2023年10月,纳入成人急诊疑似心源性胸痛且初始检查不能确定、需行ACS风险分层的研究,评估MACS、T-MACS和HE-MACS对急性心肌梗死(AMI)和30天主要不良心脏事件(MACE)的诊断性能。对AMI检测,MACS灵敏度99%(CI 97-100)、特异度19%(CI 10-32),T-MACS灵敏度98%(CI 98-99)、特异度35%(CI 29-42),HE-MACS灵敏度99%(CI 98-100)、特异度9%(CI 3-21)。对MACE检测,T-MACS灵敏度96%(CI 94-98)、特异度36%(CI 30-43)。T-MACS因高灵敏度和显著更优的特异度而综合准确率最高,作者认为其是处理急性胸痛患者极具前景的工具。

要点

  • T-MACS检测AMI:灵敏度98%(CI 98-99)、特异度35%(CI 29-42)、AUC 0.859(CI 0.824-0.887)。
  • T-MACS检测30天MACE:灵敏度96%(CI 94-98)、特异度36%(CI 30-43)、AUC 0.792(CI 0.748-0.830)。
  • MACS检测AMI:灵敏度99%(CI 97-100)、特异度19%(CI 10-32);检测MACE:灵敏度98%(CI 94-100)、特异度22%(CI 10-42)。
  • HE-MACS检测AMI:灵敏度99%(CI 98-100)、特异度9%(CI 3-21);检测MACE:灵敏度99%(CI 97-99)、特异度10%(CI 6-16)。
  • 三种MACS模型中T-MACS综合准确率最高,源于其高灵敏度与显著更优的特异度。

适用人群与场景

  • 成人急诊患者,疑似心源性胸痛且初始检查结果不能确定、需行ACS风险分层。

研究设计与关键结果

  • 系统评价与荟萃分析,检索Medline、Embase、Scopus和Web of Science自建库至2023年10月,纳入成人急诊疑似心源性胸痛且初始检查不能确定、需ACS风险分层的研究。
  • AMI检测:MACS灵敏度99%(CI 97-100)、特异度19%(CI 10-32)、AUC 0.816(CI 0.720-0.885)。
  • AMI检测:T-MACS灵敏度98%(CI 98-99)、特异度35%(CI 29-42)、AUC 0.859(CI 0.824-0.887)。
  • AMI检测:HE-MACS灵敏度99%(CI 98-100)、特异度9%(CI 3-21)、AUC 0.787(CI 0.647-0.882)。
  • MACE检测:MACS灵敏度98%(CI 94-100)、特异度22%(CI 10-42)、AUC 0.804(CI 0.659-0.897)。
  • MACE检测:T-MACS灵敏度96%(CI 94-98)、特异度36%(CI 30-43)、AUC 0.792(CI 0.748-0.830)。
  • MACE检测:HE-MACS灵敏度99%(CI 97-99)、特异度10%(CI 6-16)、AUC 0.713(CI 0.625-0.787)。
  • 三种MACS模型中T-MACS综合准确率最高,因其高灵敏度与显著更优的特异度。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析;采用QUADAS-2工具评估适用性与偏倚风险。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,T-MACS在预测AMI和MACE方面表现出很好的诊断性能,使其成为处理急性胸痛患者极具前景的工具。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Multiple decision-aiding models are available to help physicians identify acute coronary syndrome (ACS) and accelerate the decision-making process in emergency departments (EDs). This study evaluated the diagnostic performance of the Manchester Acute Coronary Syndrome (MACS) rule and its derivations, enhancing the evidence for their clinical use. A systematic review and meta-analysis was performed. Medline, Embase, Scopus, and Web of Science were searched from inception until October 2023 for studies including adult ED patients with suspected cardiac chest pain and inconclusive findings requiring ACS risk-stratification. The predictive value of MACS, Troponin-only MACS (T-MACS), or History and Electrocardiogram-only MACS (HE-MACS) decision aids for diagnosing acute myocardial infarction (AMI) and 30-day major adverse cardiac outcomes (MACEs) among patients admitted to ED with chest pain suspected of ACS. Overall sensitivity and specificity were synthesized using the 'Diagma' package in STATA statistical software. Applicability and risk of bias assessment were performed using the QUADAS-2 tool. For AMI detection, MACS has a sensitivity of 99% [confidence interval (CI): 97-100], specificity of 19% (CI: 10-32), and AUC of 0.816 (CI: 0.720-0.885). T-MACS shows a sensitivity of 98% (CI: 98-99), specificity of 35% (CI: 29-42), and AUC of 0.859 (CI: 0.824-0.887). HE-MACS exhibits a sensitivity of 99% (CI: 98-100), specificity of 9% (CI: 3-21), and AUC of 0.787 (CI: 0.647-0.882). For MACE detection, MACS demonstrates a sensitivity of 98% (CI: 94-100), specificity of 22% (CI: 10-42), and AUC of 0.804 (CI: 0.659-0.897). T-MACS displays a sensitivity of 96% (CI: 94-98), specificity of 36% (CI: 30-43), and AUC of 0.792 (CI: 0.748-0.830). HE-MACS maintains a sensitivity of 99% (CI: 97-99), specificity of 10% (CI 6-16), and AUC of 0.713 (CI: 0.625-0.787). Of all the MACS models, T-MACS displayed the highest overall accuracy due to its high sensitivity and significantly superior specificity. T-MACS exhibits very good diagnostic performance in predicting both AMI and MACE. This makes it a highly promising tool for managing patients with acute chest pain.

来源:Eur J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Roshdi Dizaji S, Ahmadzadeh K, Zarei H, et al. Performance of Manchester Acute Coronary Syndromes decision rules in acute coronary syndrome: a systematic review and meta-analysis. Eur J Emerg Med. 2024. PMID: 38864570. doi:10.1097/MEJ.0000000000001147

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。